NT_1170x120_1-11-18

mylan

Mylan to acquire Cold-EEZE

Mylan to acquire Cold-EEZE

PITTSBURGH — Mylan N.V. plans to acquire the global rights to the Cold-EEZE over-the-counter cold remedy brand from ProPhase Labs Inc. Under the agreement, Mylan’s U.S. OTC subsidiary will buy substantially all of the assets and other rights relating to the Cold-EEZE brand. Financial terms weren’t disclosed. Cold-EEZE products sold in the U.S. market include

Mylan releases Concerta generic

Mylan releases Concerta generic

PITTSBURGH — Mylan N.V. has launched methylphenidate hydrochloride extended-release tablets, a medication for attention deficit hyperactivity disorder (ADHD), in the United States. Mylan said its product, a generic version of Concerta tablets from Janssen Pharmaceuticals Inc., comes in dosages of 18 mg, 27 mg, 36 mg and 54 mg. “The launch of generic Concerta tablets

Mylan rolls out generic EpiPen to pharmacies

Mylan rolls out generic EpiPen to pharmacies

PITTSBURGH — This week, Mylan N.V. began making an authorized generic of its EpiPen epinephrine auto-injector available to pharmacies. Mylan said its generic epinephrine auto-injector, announced in late August, carries a wholesale acquisition cost (WAC) of $300 per two-pack carton, more than 50% lower than the WAC of EpiPen 2-Pak Auto-Injectors. The generic EpiPen, which

Mylan releases generics of Benicar, Benicar HCT

Mylan releases generics of Benicar, Benicar HCT

PITTSBURGH — Mylan N.V. has announced the U.S. launch of olmesartan medoxomil tablets and olmesartan medoxomil/hydrochlorothiazide tablets, two medications for high blood pressure. Mylan said the products mark the first generic versions of Benicar and Benicar HCT tablets from Daiichi Sankyo. Mylan’s olmesartan medoxomil generic comes in strengths of 5 mg, 20 mg and 40

Kaleo set to bring back Auvi-Q epinephrine injector

Kaleo set to bring back Auvi-Q epinephrine injector

RICHMOND, Va. — Pharmaceutical company Kaleo plans to reintroduce the Auvi-Q epinephrine auto-injector to the U.S. market in the first half of 2017. For emergency use in treating life-threatening allergic reactions such as anaphylaxis, Auvi-Q is expected to provide an option to the EpiPen from Mylan Inc., which has been lambasted by government officials, the

Video: Mylan CEO testifies at EpiPen hearing

Video: Mylan CEO testifies at EpiPen hearing

Mylan CEO Heather Bresch gave testimony at a hearing Wednesday afternoon by the House Committee on Oversight and Government Reform over the sharp price hike for the EpiPen epinephrine auto-injector since the company acquired the product in 2007. The EpiPen is used for treating anaphylaxis, a potentially life-threatening allergic reaction. Committee chairman Jason Chaffetz (R.,

Impax highlights its generic epinephrine auto-injector

Impax highlights its generic epinephrine auto-injector

HAYWARD, Calif. — Impax Laboratories Inc. is spotlighting its generic epinephrine auto-injector amid a public outcry over the cost of emergency medication for anaphylaxis, a potentially life-threatening allergic reaction. In what Impax called an update, the company said it’s providing additional information to patients, doctors and customers about its epinephrine injection auto-injector in 0.15-mg and

Mylan set to launch generic EpiPen

Mylan set to launch generic EpiPen

PITTSBURGH — In what chief executive officer Heather Bresch called “an extraordinary commercial response,” Mylan N.V. plans to release a generic version of its EpiPen epinephrine auto-injector for anaphylaxis, answering public demands to lower the cost of the potentially life-saving product. Mylan said Monday that its U.S. subsidiary expects to roll out the generic EpiPen

Senators question pricing of Mylan’s EpiPen

Senators question pricing of Mylan’s EpiPen

NEW YORK — Senate leaders have voiced concerns about a price surge for Mylan Inc.’s EpiPen, an epinephrine auto-injector for treating anaphylaxis, or potentially life-threatening allergic reactions. Sen. Chuck Grassley (R, Iowa), chairman of the Senate Judiciary Committee, and Sens. Susan Collins (R., Maine) and Claire McCaskill (D., Mo.), chairman and ranking member of the

Mylan closes acquisition of Meda

Mylan closes acquisition of Meda

PITTSBURGH — Mylan N.V. has completed its $9.9 billion deal to acquire Sweden-based Meda AB. Mylan had received Federal Trade Commission clearance for the transaction in late July. The deal was announced in February. The combination of Mylan and Meda creates a leading pharmaceutical company with a strong portfolio of brand-name and generic drugs and

Mylan launches pair of new generics in U.S.

Mylan launches pair of new generics in U.S.

PITTSBURGH — Mylan N.V. this week introduced two new generic drugs in the U.S. market. On Monday, the company announced final Food and Drug Administration approval for dextroamphetamine sulfate extended-release capsules — in dosages of 5 mg, 10 mg and 15 mg — and finasteride tablets 1 mg. Mylan’s dextroamphetamine sulfate ER capsules are a

FTC clears Teva-Allergan, Mylan-Meda acquisitions

FTC clears Teva-Allergan, Mylan-Meda acquisitions

NEW YORK — The Federal Trade Commission has given its approval to two major pharma acquisitions: Teva Pharmaceutical Industries Ltd.’s $40 billion deal to buy Allergan plc’s generics business and Mylan N.V.’s $9.9 billion deal to acquire Meda AB. Teva said that with the FTC’s acceptance of the proposed consent order, the company has satisfied

Mylan releases Fenoglide generic

Mylan releases Fenoglide generic

PITTSBURGH — Mylan N.V. has launched fenofibrate tablets 40 mg and 120 mg, a cholesterol-lowering drug, in the United States. Mylan said Wednesday that its fenofibrate product is a generic version of Fenoglide tablets from Santarus. Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides and

H.D. Smith Jr. honored with Nexus Award

H.D. Smith Jr. honored with Nexus Award

COLORADO SPRINGS, Colo. — Henry Dale Smith Jr., chairman and chief executive officer of H.D. Smith Holding Co., has received the 2016 Nexus Award for Lifetime Achievement from the HDA Research Foundation. Smith was presented the award, the pharmaceutical distribution industry’s highest individual honor, at the Healthcare Distribution Alliance (HDA) 2016 Business and Leadership Conference